Effect of SGLT2 Inhibitors + DPP‐4 Inhibitors on Urine Microbiota in Type 2 Diabetes
Diabetes/Metabolism Research and Reviews · 2026
DOI: 10.1002/dmrr.70127 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Diabetes/Metabolism Research and Reviews, 2026. Verfasst von Marco Calvigioni und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Sodium-Glucose Transporter 2 Inhibitors, Dipeptidyl-Peptidase IV Inhibitors, Microbiota. Die Arbeit nennt 38 Literaturangaben.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aims
A reduced compliance, due to urogenital minor infections, frequently compromises the clinical efficacy of SGLT2 inhibitors in subjects with type 2 diabetes (T2D). The combined use of SGLT2 inhibitors and dipeptidyl‐peptidase four inhibitors seems to reduce the incidence of such side effects. We evaluated how these drugs, alone or in combination, might influence resident urinary microbiota. Materials and Methods An open label, randomised clinical study was conducted on 30 T2D individuals for 12 weeks to compare the impact of Empagliflozin and Empagliflozin/Linagliptin on clinical parameters and urinary microbiota. Fifteen healthy individuals served as baseline controls. The composition of urinary bacterial populations was evaluated by Real‐Time quantitative PCR and 16S rRNA gene sequencing.
Results
BMI was reduced by both treatments, while fasting glucose and HbA1c significantly improved only with the combination. At baseline, T2D showed a higher total bacterial load and abundance of Bacillota than controls. The prevalence and proportion of bacterial species profoundly differed between the groups, revealing a urinary dysbiosis in T2D. A different effect of Empagliflozin alone or combined with Linagliptin on microbial populations was observed: Empagliflozin increased the total bacterial load of Bacillota and Aerococcus , while the combination therapy restored a microbial community similar to that of controls, further reducing the prevalence of potential urinary pathogens.
Conclusions
In T2D subjects, the combination of Empagliflozin and Ligandliptin might help in restoring a normal composition of the urinary microbiota, likely improving compliance and persistence in therapy with SGLT2 inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.
- Department of Experimental and Clinical Medicine, University of Firenze, Firenze, Italy.
- Department of Surgical, Medical, Molecular Pathology and Critical Area University of Pisa, Pisa, Italy.
ORCID-Profile: Chiara Rossi, Anna Solini
Zitieren
APA
Calvigioni, M., Biancalana, E., Rossi, C., Mazzantini, D., Celandroni, F., Ghelardi, E., & Solini, A. (2026). Effect of SGLT2 Inhibitors + DPP‐4 Inhibitors on Urine Microbiota in Type 2 Diabetes. Diabetes/Metabolism Research and Reviews. https://doi.org/10.1002/dmrr.70127
Vancouver
Calvigioni M, Biancalana E, Rossi C, Mazzantini D, Celandroni F, Ghelardi E, et al. Effect of SGLT2 Inhibitors + DPP‐4 Inhibitors on Urine Microbiota in Type 2 Diabetes. Diabetes/Metabolism Research and Reviews. 2026. doi:10.1002/dmrr.70127
BibTeX
@article{Calvigioni2026,
author = {Calvigioni, Marco and Biancalana, Edoardo and Rossi, Chiara and Mazzantini, Diletta and Celandroni, Francesco and Ghelardi, Emilia and Solini, Anna},
title = {Effect of SGLT2 Inhibitors + DPP‐4 Inhibitors on Urine Microbiota in Type 2 Diabetes},
journal = {Diabetes/Metabolism Research and Reviews},
year = {2026},
doi = {10.1002/dmrr.70127}
}
EUVIMED